Design, synthesis and cytotoxic evaluation of novel bis-thiazole derivatives as preferential Pim1 kinase inhibitors with in vivo and in silico study

References

• WHO Cancer: Key Facts. 2021. https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• US NIH – National Cancer Institute Cancer Statistics. 2016. https://www.cancer.gov/about-cancer/understanding/statistics
   Google Scholar
• Brighton D, Wood M. In: Brighton D, Wood M, editors. The royal marsden hospital hand book of cancer chemotherapy. London, New York (NY), Oxford: Elsevier Churchill Livingstone; 2005. p. 1–17.
   Google Scholar
• Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, et al. Pim1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016;22(11):1303–1313.
   PubMed Web of Science ®Google Scholar
• Gapter LA, Magnuson NS, Ng K-y, Hosick HL. Pim-1 kinase expression during mrine mammary development. Biochem Biophys Res Commun. 2006;345(3):989–997.
   PubMed Web of Science ®Google Scholar
• Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005;3(8):443–451.
   PubMed Web of Science ®Google Scholar
• Wang B, Huang C, Liu L. Pim1 kinase inhibitors exert anti-cancer activity against Her2-positive breast cancer cells through downregulation of Her2. Front Pharmacol. 2021;12:614673.
   PubMed Web of Science ®Google Scholar
• Li J, Loveland BE, Xing PX. Anti-Pim-1 Mab inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survival. Cell Immunol. 2011;272(1):87–93.
   PubMed Web of Science ®Google Scholar
• Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999;20(4):501–534.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Lu J, Cai Q. EBNA3C augments Pim-1 mediated phosphorylation and degradation of P21 to promote B-cell proliferation. PLoS Pathog. 2017;10:e1004304.
   Google Scholar
• Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating P27kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008;68(13):5076–5085.
   PubMed Web of Science ®Google Scholar
• Jessus C, Ozon R. Function and regulation of CDC25 protein phosphate through mitosis and meiosis. Prog Cell Cycle Res. 1995;1:215–228.
   PubMedGoogle Scholar
• Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol. 2010;78(2):310–318.
   PubMed Web of Science ®Google Scholar
• Xie Y, Xu K, Linn DE. The 44-KDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2008;283:3349–3356.
   PubMed Web of Science ®Google Scholar
• Kim KT, Baird K, Ahn JY. Pim-1 is up-regulated by constitutively activated Flt3 and plays a role in FLT3-mediated cell survival. Blood. 2005;105:1759–1767.
   PubMed Web of Science ®Google Scholar
• Qian KC, Wang L, Hickey ER. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem. 2005;280:6130–6137.
   PubMed Web of Science ®Google Scholar
• Jacobs MD, Black J, Futer O, Swenson L, Hare B, Fleming M, Saxena K. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by Ly294002. J Biol Chem. 2005;280(14):13728–13734.
   PubMed Web of Science ®Google Scholar
• Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, Lee WH, von Delft F, Meggers E, Knapp S. Crystal structure of the Pim2 kinase in complex with an organoruthenium inhibitor. PLoS One. 2009;4(10):e7112.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Moreno BH. Improved antitumour activity of immunotherapy with B-RAF and MEK inhibitors in BRAF(V600e) melanoma. Sci Transl Med. 2015;18(7):279.
   Web of Science ®Google Scholar
• Li X, He Y, Ruiz CH, Koenig M, Cameron MD, Vojkovsky T. Characterization of dasatinib and its structural analogs as Cyp3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos. 2009;37(6):1242–1250.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lucena D, Gaboriau F, Rivault F, Schalk IJ, Lescoat G, Mislin GLA. Synthesis and biological properties of iron chelators based on a Bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (Bhptc) scaffold. Bioorg Med Chem. 2010;18(2):689–695.
   PubMed Web of Science ®Google Scholar
• Farghaly TA, El-Metwaly N, Al-Soliemy AM. Synthesis, molecular docking and antitumor activity of new dithiazoles. Polycycl Aromat Compd. 2019;41(8):1–17.
   Web of Science ®Google Scholar
• Gong C-J, Gao A-H, Zhang Y-M, Su M-B, Chen F, Sheng L, Zhou Y-B, Li J-Y, Li J, Nan F-J. Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy. Eur J Med Chem. 2016;112:81–90.
   PubMed Web of Science ®Google Scholar
• Lagoja IM, Nauwelaerts K, Mahieu CB. Synthesis and leukemia cell growth inhibition of a series of 1,3-dithiazolylbenzene derivatives. Collect Czech Chem Commun. 2004;69:1491–1498.
   Google Scholar
• Dawood KM, Raslan MA, Abbas AA, Mohamed BE, Abdellattif MH, Nafie MS, Hassan MK. Novel bis-thiazole derivatives: synthesis and potential cytotoxic activity through apoptosis with molecular docking approaches. Front Chem. 2021;9:694870.
   PubMed Web of Science ®Google Scholar
• Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett. 2012;22(14):4599–4604.
   PubMed Web of Science ®Google Scholar
• Ishchenko A, Zhang L, Le Brazidec J-Y, Fan J, Chong JH, Hingway A, Raditsis A, Singh L, Elenbaas B, Hong VS, et al. Structure based design of low-nanomolar Pim kinase inhibitors. Bioorg Med Chem Lett. 2015;25(3):474–480.
   PubMed Web of Science ®Google Scholar
• The Binding Database. 2022.
   Google Scholar
• Chaudhary HS, Pujari HK. Spirothiazolidones: Part I; 5,5'-spirohi-(2-arylimino-4-thiazolidones). Indian J Chem. 1968;6( 9):488–489.
   Google Scholar
• Achary TE, Panda CS, Nayak A. Synthesis of bis-thiazolidone and bis-thio-hydantoin and their derivatives from m-phenylene diamine. J Indian Chem Soc. 1975;52(11):1065–1066.
   Web of Science ®Google Scholar
• Mamedov VA, Khafizova EA, Berdnikov EA. Fused polycyclic nitrogen containing heterocycles. Part 15. 1,3-bis(4-(4hydroxy-4-methoxycarbonyl-3,5-diphenylthiazolidin-2-ylideneamino)benzene in the synthesis of thiazolo[3,4-a]quinoxalines. Russ Chem Bull. 2006;55(9):1670–1676.
   Web of Science ®Google Scholar
• DTP: Developmental Therapeutics Program NCI-60 Screening Methodology: NCI 60 Cell One-Dose Screen. 2022. https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm#:∼:text=NCI%2060%20Cell%20Five%2DDose,and%202%20mM%20L%2Dglutamine
   Google Scholar
• Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem. 1989;182(1):16–19.
   PubMed Web of Science ®Google Scholar
• Meeker TC, Nagarajan L, Ar-Rushdi A. Cloning and characterization of the human Pim‐1 gene: a putative oncogene related to the protein kinases. J Cell Biochem. 1987;35(2):105–112.
   PubMed Web of Science ®Google Scholar
• Friedmann M, Nissen MS, Hoover DS, Reeves R, Magnuson NS. Characterization of the proto-oncogene Pim‐1: kinase activity and substrate recognition sequence. Arch Biochem Biophys. 1992;298(2):594–601.
   PubMed Web of Science ®Google Scholar
• Fekry MI, Ezzat SM, Salama MM, Alshehri OY, Al-Abd AM. Bioactive glycoalkaloides isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells. Sci Rep. 2019; 9(1):1746.
   PubMedGoogle Scholar
• Guideline OO. Test 425: acute oral toxicity—up-and-down procedure. OECD Guidel Chem. 2001;2:12–16.
   Google Scholar
• Ahmed EY, Abdelhafez OM, Zaafar D. Antitumor and multikinase inhibition activities of some synthesized coumarin and benzofuran derivatives. Arch Pharm. 2022;355:e2100327.
   PubMed Web of Science ®Google Scholar
• Bancroft JD, Gamble M. In: Theory and practice of histological techniques. 6th ed. New York (NY): Elsevier Health Sciences Churchill Livingstone Elsevier; 2008.
   Google Scholar
• Hsu S, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol. 1981;75(6):816–821.
   PubMed Web of Science ®Google Scholar
• Chen DL, Engle JT, Griffin EA, Miller JP, Chu W, Zhou D, Mach RH. Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer. Mol Imaging Biol. 2015;17(3):384–393.
   PubMed Web of Science ®Google Scholar
• Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Habashneh AY, El-Abadelah Mustafa MM, Zihlif MA. Synthesis and antitumor activities of some new N1- (flavon-(flavon-6-6-Yl)Yl)amidrazone derivaamidrazone derivatives. Arch Pharm. 2014;347(6):415–422.
   PubMed Web of Science ®Google Scholar
• Wu Y. In: Library WO, editor. Progress in heterocyclic chemistry. Chapter 5.5 - Five-membered ring systems: With N and S (Se) atoms. New York (NY): Wiley Online Library; 2011. p. 5.
   Google Scholar
• Hantzsch A, Weber JH. Ueber verbindungen des thiazols (Pyridins Der Thiophenreihe). Eur J Inorg Chem. 1887;20(2):3118–3132.
   Google Scholar
• Cohen P. Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1(4):309–315.
   PubMed Web of Science ®Google Scholar
• Dumas J. Protein kinase inhibitors: emerging pharmacophores 1997–2000. J Exp Opin Ther Patents. 2001;11(3):405–429.
   Web of Science ®Google Scholar
• Minch MJ. An introduction to hydrogen bonding (Jeffrey, George A). J Chem Educ. 1999;76(6):759.
   Google Scholar
• Dalvit C, Invernizzi C, Vulpetti A. Fluorine as a hydrogen-bond acceptor: experimental evidence and computational calculations. Chemistry. 2014;20(35):11058–11068.
   PubMed Web of Science ®Google Scholar
• Howard JA, J.Hoy V, O'Hagan D. How good is fluorine as a hydrogen bond acceptor? Tetrahedron. 1996;52(38):12613–12622.
   Web of Science ®Google Scholar
• Parker LJ, Watanabe H, Tsuganezawa K, Tomabechi Y, Handa N, Shirouzu M, Yuki H, Honma T, Ogawa N, Nagano T, et al. Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012;68(Pt 8):860–866.
   PubMedGoogle Scholar
• Marcotte DJ, Silvian LF. RCSB: The Protein Data Bank: RCSB: PDB. 2015.
   Google Scholar
• Hostettmann K, Dey PM, Harborne JB. Assays for bioactivity. In: Hostettmann K, editor. Methods in plant biochemistry. 6th ed. Vol. 6. London: Academic Press; 1991. p. 71–133.
   Google Scholar